[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$hlbbf Graphic](https://lunarcrush.com/gi/w:26/t:$hlbbf.png) $hlbbf

FDA questions the efficacy of Rexulti, causing a potential speedbump. Praxis receives Breakthrough Therapy Designation for relutrigine, which may boost the stock.

### About $hlbbf
This is a summary of social media activity related to the stock ticker $hlbbf.  

### Insights [#](/topic/$hlbbf/insights)
- $hlbbf Engagements hit a high of XXXXX for the day
- $hlbbf Engagements hit an all time of XXXXX for the day

### Engagements: XXX [#](/topic/$hlbbf/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$hlbbf/c:line/m:interactions.svg)  
[Engagements 24-Hour Chart Data](/topic/$hlbbf/time-series/interactions.tsv)  
**Current Value**: XXX  
**Daily Average**: XX  
**1 Month**: XXXXX +320%  
**1-Year High**: XXXXX on 2025-07-18  
**1-Year Low**: X on 2025-05-01  

| Social Network | X   |
| -------------- | -   |
| Engagements    | XXX |
  

  
  
### Mentions: X [#](/topic/$hlbbf/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$hlbbf/c:line/m:posts_active.svg)  
[Mentions 24-Hour Chart Data](/topic/$hlbbf/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**1 Week**: X no change  
**1 Month**: X +100%  
**1-Year High**: X on 2025-05-03  
**1-Year Low**: X on 2025-04-29  

| Social Network | X |
| -------------- | - |
| Mentions       | X |
  

  
  
### Creators: X [#](/topic/$hlbbf/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$hlbbf/c:line/m:contributors_active.svg)  
[Creators 24-Hour Chart Data](/topic/$hlbbf/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $hlbbf in the last XX hours which is no change from in the previous XX hours
**Daily Average**: X  
**1 Week**: X no change  
**1 Month**: X +200%  
**1-Year High**: X on 2025-07-10  
**1-Year Low**: X on 2025-04-29  

**Top assets mentioned**
In the posts about $hlbbf in the last XX hours

[Biogen Inc (BIIB)](/topic/$biib)
[Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix)
[Xenon Pharmaceuticals Inc (XENE)](/topic/$xene)
[Biohaven Pharmaceutical Holding Company Ltd. (BHVN)](/topic/$bhvn)
[Neurocrine Biosciences, Inc. (NBIX)](/topic/neurocrine-biosciences-inc)
[Piper Sandler Companies (PIPR)](/topic/$pipr)
[Biogen Inc (BIIB)](/topic/biogen-inc)
[Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli)
[Jazz Pharmaceuticals, Inc. (JAZZ)](/topic/$jazz)
[Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn)

**Top topics mentioned**
In the posts about $hlbbf in the last XX hours

[stocks healthcare](/topic/stocks-healthcare), [$otsky](/topic/$otsky), [$ucbjf](/topic/$ucbjf), [$biib](/topic/$biib), [$aqst](/topic/$aqst), [nyc](/topic/nyc), [investment](/topic/investment), [$hlubf](/topic/$hlubf), [$lbph](/topic/$lbph), [$nbix](/topic/$nbix), [$drug](/topic/$drug), [$rapp](/topic/$rapp), [breakthrough](/topic/breakthrough), [$prax](/topic/$prax), [hc](/topic/hc), [$xene](/topic/$xene), [$bhvn](/topic/$bhvn), [neurocrine biosciences inc](/topic/neurocrine-biosciences-inc), [$pipr](/topic/$pipr), [biogen inc](/topic/biogen-inc), [$dnli](/topic/$dnli), [$jazz](/topic/$jazz), [$4768t](/topic/$4768t), [$4578t](/topic/$4578t), [ads](/topic/ads), [wegovy](/topic/wegovy), [$regn](/topic/$regn), [$sny](/topic/$sny), [$lly](/topic/$lly), [$jnj](/topic/$jnj), [$nvo](/topic/$nvo), [$abbv](/topic/$abbv), [johnson johnson](/topic/johnson-johnson), [eli lilly](/topic/eli-lilly), [sanofi](/topic/sanofi), [regeneron pharmaceuticals inc](/topic/regeneron-pharmaceuticals-inc), [$bmy](/topic/$bmy)

### Top Social Posts [#](/topic/$hlbbf/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"H.C. Wainwright reitd $PRAX Buy-$105 after Praxis announced that FDA had granted Breakthrough Therapy Designation (BTD) for relutrigine for the treatment of pediatric patients with SCN2A and SCN8A DEEs. $RAPP $XENE $BHVN $DRUG $NBIX ( $LBPH - $HLBBF $HLUBF) H.C. Wainwright said in its note: "While investor attention has largely been on the upcoming readout of vormatrigine's RADIANT study in focal onset seizures there has been increasing appreciation that relutrigine is deserving of attention. There's a case to be made that relutrigine's commercial potential in DEEs may even exceed"  
[@Quantumup1](/creator/x/Quantumup1) on [X](/post/tweet/1946188742093586828) 2025-07-18 12:42:09 UTC 3519 followers, 1292 engagements


"$OTSKY $HLBBF - Otsuka Lundbecks PTSD Bid for Rexulti Hits Speedbump as FDA Questions Efficacy -"  
[@MarcJacksonLA](/creator/x/MarcJacksonLA) on [X](/post/tweet/1945837764332912820) 2025-07-17 13:27:29 UTC 7059 followers, XXX engagements